Podcasts about Matterhorn

CONTACT US TODAY! PATREON: http://www.patreon.com/wttmpodcast TikTok: https://www.tiktok.com/@windowtothemagic YouTube: http://youtube.com/windowtothemagic Email: podcast@windowtothemagic.com Voicemail: 1-307-GET-WTTM (438-9886)  On this episode, Part 2 of 3, Paul takes on Fantasyland at Disneyland.  Join Paul as he continues exploring Fantasyland and then does every Fantasyland attraction (except Matterhorn) in near real time.   This is classic WTTM podcast fun, when we go in and literally share the in-park experience with you.   Very little editing here... just binaural audio of the heart of Walt's original Magic Kingdom.  Enjoy!!  62 mins ))HD BINAURAL((

Risk Isn't Reckless | Elite Risk Management with SuperFrenchie What does it take to make decisions when the margin for error is zero? In this episode of The Heartbeat for Hire Podcast, Lyndsay sits down with Matthias Giraud — better known as SuperFrenchie — two-time world record–holding ski BASE jumper, professional alpinist, and the only person in history to ski BASE jump the Alps Trilogy: Eiger, Matterhorn, and Mont Blanc. Known for GoPro's first viral avalanche cliff jump and featured on 60 Minutes, CNN Headline News, and international media worldwide, Matthias has amassed over 100+ million cumulative views across social, YouTube, and global television. But this conversation isn't about adrenaline. It's about discipline. It's about fear. It's about clarity under pressure. This episode explores the psychology behind extreme performance, dismantles the myth of the "adrenaline junkie," and reframes risk as a leadership competency — not a personality trait. Episode Summary In this episode of The Heartbeat for Hire Podcast, Lynz welcomes two-time world record-holding ski BASE jumper Matthias Giraud, famously known as "SuperFrenchie." Matthias shares his journey from the French Alps to becoming a professional mountain athlete and the only person to ski BASE jump the "Alps Trilogy" — the Eiger, Matterhorn, and Mont Blanc. The conversation dives deep into the psychology of extreme sports, debunking the myth of the adrenaline addict and instead focusing on elite risk management, the necessity of fear, and finding fulfillment through self-calibration. In This Episode, You'll Learn: 1️⃣ How elite performers evaluate risk before emotion takes over 2️⃣ Why fear is not the enemy — but a required data point 3️⃣ How preparation, humility, and presence create sustainable performance Key Takeaways Fulfillment Over Adrenaline The Power of Self-Calibration Failure as a Teacher Honor Your Inner Child Personal Accountability Episode Chapters [00:00] – The Illusion of Arrogance [03:15] – Redefining the "Adrenaline Junkie" [06:04] – The Origin of "Super Frenchy" [08:50] – Honoring the Inner Child [12:15] – Self-Calibration vs. Failure [14:45] – The "Weather Report" Philosophy [17:30] – Managing Fear and Anxiety [20:10] – The Alps Trilogy [23:55] – Vulnerability in Leadership [27:20] – The Concept of "Active Waiting" [30:45] – Defining Success [33:15] – Final Thoughts and Where to Follow About Matthias Giraud Matthias Giraud (SuperFrenchie) is a professional mountain athlete specializing in alpinism, steep skiing, and BASE jumping. He is a two-time world record holder for highest ski BASE jump and has completed numerous first descents and ski BASE jumps worldwide, including: First ski BASE jump off Eiger First ski BASE jump off Matterhorn First ski BASE jump off Mont Blanc First ski BASE jump off Mt. Hood First Night Ski BASE Jump He has performed and spoken for global organizations including Apple, Facebook, and NetApp and continues to produce high-engagement content across social and YouTube. Follow Matthias: Instagram: @superfrenchieofficial

Von Berg-Emojis und Gipfel-Rekorden, von Kletterpartien mit VR-Brille bis zu echt-eisigen Todeszonen.

Are you planning your Swiss itinerary and wondering “Is Zermatt worth visiting?” This episode will answer that question - with a resounding ‘yes'. I'm joined by local expert, Viviane Zellweger, for a winter walk in Zermatt to get a local's perspective on the best things to do in Zermatt.Viviane answers the questions most first-time visitors ask, from “Where is Zermatt in Switzerland?” to the best ways to experience its world-famous mountains, how to get to Zermatt and what to do there.Viviane shares insider tips on unique activities like walking the picturesque Pensioners' Trail (perfect if you're looking for free things to do in Zermatt), visiting the historic Hinterdorf area in Zermatt village, and exploring the fascinating Matterhorn Museum (Zermatlantis). You'll also get the lowdown on Zermatt hiking trails and learn how to enjoy the magic of the Zermatt mountains no matter your fitness level.Not a skier? No problem winter activities in Zermatt for non-skiers, including scenic walks, snowshoeing, cross-country skiing, and even spa indulgence. Viviane also shares her tips for where to eat in Zermatt, recommending delicious Swiss classics at mountain restaurants. Join us for a virtual winter hike in Zermatt, gaze at the Matterhorn, and get inspired for your Swiss adventure. Don't miss the practical tips that will make planning your Zermatt trip easier than ever, no matter what time of year you plan to visit!You can watch the video of this episode on YouTube.Happy travels,Carolyn

In this episode, I'm taking you to Switzerland and to the Valais Canton. I recently returned from a trip to three very different ski resorts: Les Marécottes, Verbier, and Bettmeralp. Each was beautiful in its own way, but it was the Aletsch Arena that truly stayed with me. It has been described as an insider's secret resort or a hidden gem. But it is well known to the Swiss and it's where they go to ski.In this episode, I'm joined by local expert David Kestens, who helps bring the Aletsch Arena to life. We talk about the car-free mountain villages of Riederalp, Bettmeralp, and Fiescheralp. David gives us an insiders guide to the insiders secret resort. I found myself deeply drawn to the Aletsch Arena, not just for its scenery, but for the feeling it creates. We also explore what the region offers throughout the year, from peaceful alpine walks in summer to skiing and snowshoeing in the winter months.The Aletsch Arena is home to the Great Aletsch Glacier, the longest glacier in the Alps, and forms part of one of Switzerland's most remarkable UNESCO World Heritage Sites. Surrounded by more than forty peaks rising over four thousand metres including the Matterhorn, Mont Blanc, and the Eiger. It's a place that naturally encourages you to slow down and take a breath.We also chat about Les Marécottes, and about what is possibly Switzerland's most famous ski resort, Verbier. A place that's very personal to me. I've visited Verbier many times over the years and it's where I first learned to ski.Join me as we explore why the Aletsch Arena, and the wider Valais region, are among the most special places to visit, from the stunning mountain villages to the wonderful train, and discover why they may just earn a place on your Switzerland bucket list.If you haven't already, I'd ask you to give me a follow on whichever platform you listen to your podcasts and you will be the first to get a new episode.Stays Marecottes - https://www.zoo-alpin.ch/fr/zoo-boutique-hotelButtmeralps - https://www.sporting-bettmeralp.ch Fergal O'Keeffe is the host of Ireland's No.1 Travel Podcast Travel Tales with Fergal which is now listened to in 140 countries worldwide. The podcast aims to sharesoul-lifting travel memoirs about daydream worthy destinations. Please follow me onInstagram @traveltaleswithfergalFacebook @traveltaleswithfergalTwitter @FergalTravelYouTube @traveltaleswithfergal Hosted on Acast. See acast.com/privacy for more information.

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

CONTACT US TODAY! PATREON: http://www.patreon.com/wttmpodcast TikTok: https://www.tiktok.com/@windowtothemagic YouTube: http://youtube.com/windowtothemagic Email: podcast@windowtothemagic.com Voicemail: 1-307-GET-WTTM (438-9886)  On this episode, Part 1 of 3, Paul takes on Fantasyland at Disneyland.  Join Paul as he walks up Main Street USA, enters Fantasyland and then does every Fantasyland attraction (except Matterhorn) in near real time.   This is classic WTTM podcast fun, when we go in and literally share the in-park experience with you.   Very little editing here... just binaural audio of the heart of Walt's original Magic Kingdom.  Enjoy!!  98 mins ))HD BINAURAL((

Bonita Norris became the youngest woman to reach both the summit of Mt Everest at just 22 and the North Pole at 23, and her story is nothing short of extraordinary. In this episode, she shares the journey that took her from school trips in North Wales to climbing some of the world's highest peaks, navigating extreme environments, and pushing the limits of what's possible. Bonita reflects on the early steps that built her career in mountaineering—starting with beginner climbing courses, funding her expeditions, and preparing for the Himalayan peaks. She opens up about the mental and physical challenges of summiting Everest, managing fear in remote and hostile environments, and how these experiences shaped her life and perspective. Now a mother of two, Bonita also discusses how she balances adventure with family life, inspiring her children to embrace courage and curiosity. From attempting K2 to climbing the Matterhorn after an eight-year hiatus, she emphasises the importance of showing up, trusting the process, and meeting opportunity with determination. Whether you're chasing literal mountains or metaphorical ones in your own life, Bonita's insights, lessons in bravery, and personal stories will motivate you to take the next bold step. ***  New episodes of the Tough Girl Podcast drop every Tuesday at 7 AM (UK time)! Make sure to subscribe so you never miss the inspiring journeys and incredible stories of tough women pushing boundaries.  Do you want to support the Tough Girl Mission to increase the amount of female role models in the media in the world of adventure and physical challenges? Support via Patreon! Join me in making a difference by signing up here: www.patreon.com/toughgirlpodcast.  Your support makes a difference.  Thank you x *** Show notes Who is Bonita  The youngest person to have reached both the summit of Mt Everest (age 22) and the North Pole (age 23) Book: The Girl Who Climbed Everest (2022)  Mother of 2 children Growing up and her early years  Going on a school trip to North Wales and loving every moment of hiking in the mountains  Finishing her A'levels and going off to South America to climb to Machu Picchu at 18 Not realising she could make a career out of mountaineering Alison Hargreaves's dying on K2 in 1995  Mothers and taking risks Being in her 2nd year at university and going to a mountaineering talk at the Royal Geographical Society  Realising that she wanted to climb and wanting to climb Mt Everest  I don't know how, but I'm going to make it happen Being inspired and maintaining the inspiration/motivation Why it felt so meaningful  2 years - 24 months to gain the skills, knowledge and funding Starting with a beginners climbing course Working backwards from her goal Completing the smaller milestones and trusting in the process Funding and paying for everything Heading off on her first Himalayan Expedition - Manaslu (eighth-highest mountain in the world at 8,163 metres (26,781 ft)) Getting a job, using her student loan and receiving a grant from her university Having 6 months to find £50k to join her team going to Everest. Getting out of bed bad making another call Speaking with Capital FM on the radio How everything turned around Getting the money, getting the sponsorship Why you don't need to be an Olympic Athlete to climb Everest  Why you need to work on the actual problem - don't work around the problem  Fitness before heading of to Nepal  Doing multi-days of training without rest If you want to get good at climbing mountains, climb mountains Reflecting back on the experience  Worrying about what may go wrong on the mountain Reaching the summit and how it's changed her life Understanding the risks at 22 Thoughts on letting her children climb Everest Climbing Everest with her daughter in the future Attempting to climb K2 and managing fear in remote, hostile environments Encouraging bravery and courage in her children  Climbing the Matterhorn in 2025 after 8 years off climbing  Not knowing if she would still enjoy it Taking the time to figure out what is next How you can connect with Bonita Final words of advice  Put yourself out there and luck will meet you half way  You have to show up   Social Media Website: www.bonita-norris.com  Linkedin: Bonita Norris     

Beatrice Egli isst zuerst die Waffeln – dann spricht sie über Tourpläne, das Matterhorn, Kritik, die an ihr abprallt und ihren Po formt, Durchhalten trotz letzter Plätze und warum sie Energie am liebsten offline auftankt. Sie reagiert gewohnt charmant auf die Frage, wie es mit Florian Silbereisen läuft. Dazu: Reisen mit XXL-Koffern, geniale Pack-Hacks, Aftershowpartys ohne sie, flüstern als Erotikfaktor und ganz viel Herz, Haltung und Humor. Viel Spaß mit der neuen Folge von "Mit den Waffeln einer Frau".

This week on the podcast, Zach Kazan is joined by Kat Shoulders and Liam O'Donnell to peel back the curtain on watch press trips. Zach just got back from Colorado with Oris, so the topic is front of mind. We reached out to members of our Worn & Wound+ Slack channel to solicit questions on press trips, how they work, and how they influence (or don't influence) our coverage of brands and their watches. Let us know if you have any additional questions about press trips – this is a fun topic to discuss and this proved to be a great discussion. Hit us up in the comments with your thoughts.To stay on top of all new episodes, you can subscribe to The Worn & Wound Podcast on all major platforms including Apple Podcasts, Stitcher, Spotify, and more. You can also find our RSS feed here.And if you like what you hear, then don't forget to leave us a review.If there's a question you want us to answer you can hit us up at info@wornandwound.com, and we'll put your question in the queue. Show Notes Oris Introduces the New Big Crown Pointer Date “Bullseye”Out of Office: Exploring the Canadian Rockies with Citizen's Team PromasterJean-Claude Biver, the Matterhorn, and Carbon Fiber with Some Color: A Few Days in Zermatt with Norqain and the New Wild One

We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers. This episode covers FGFR inhibitors (Bemartizumab), updates on the MATTERHORN trial, the use of immunotherapy with trastuzumab and FLOT in HER2-positive localised oesophageal carcinoma, and investigates the use of TKIs and the novel drug nofazinlimab for those with unresectable or metastatic hepatocellular carcinoma.A jam-packed episode that aims to over-deliver on information, laughter, and hope.2026 is going to be a big one!Studies:FORTITUDE-101MATTERHORNPHERFLOT/IKF-053NCT04669496For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

We're kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026. We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease. Key topics covered in this episode: ● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer ● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer ● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC ● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer Tune in for this dense, insightful recap and stay ahead of the curve. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more expert analysis on treatment algorithms and major conference highlights! #OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast

Gary and Shannon kick off Hour 1 in full NFL playoff mode, admitting the emotional void left by the absence of Monday Night Football and bracing for the long offseason ahead. They react to a wild NBA moment as Steve Kerr gets ejected with Snoop Dogg on the call, then shift to breaking news with the sudden death of Rep. Doug LaMalfa, reflecting on legacy versus partisan noise. The conversation moves through foreign policy, including why Mexico is not Venezuela and eyebrow-raising talk about Greenland and NATO — before turning lighter as Gary’s dog Peter becomes an NFL playoff picker for social media. The hour wraps with the latest chapter in Lenny Dykstra’s saga and listener talkbacks about line-cutting disasters at Disneyland, culminating in a debate over the Matterhorn ride and the unforgettable discovery of the “abdominal bears.”See omnystudio.com/listener for privacy information.

What a weird day at work. Johnny in fact is not too busy to pick his own lottery numbers. So heisty.See omnystudio.com/listener for privacy information.

Carrie and Molly welcome you to listen to this replay from their Wallowa series, which does indeed require a visit to the emergency department. Join in and hear how it all goes down! The day begins with big mileage and cruisey trails, but things take a turn when climbing the Matterhorn. The sisters learn how to deal with mental fatigue and assess together when it is better to go on and when it is appropriate to stop. A member of the trio also suffers a medical issue leaving the group to give first aid and work through the issue together. In between there are also some fun stories and laughter!

von Anna Wallner. 180 Politiker, Intellektuelle und Wissenschaftler trafen sich Anfang Dezember beim Summit „Le Grand Continent“ zwischen Matterhorn und Montblanc, um abseits der Öffentlichkeit über Europas Wehrhaftigkeit, das neue Verhältnis Europas zu den USA zu reden. Presse“-Außenpolitikredakteurin Susanna Bastaroli war dabei und erzählt im Podcast davon.

Send us a textBreaking news rarely hits mountain running like this. The World Skyrunner Series is officially returning to the United States, and the Beast of Big Creek on Washington's Olympic Peninsula is the stage. We dive straight into what makes this 23K course so compelling: sustained grades exceeding 20 percent, a clean up-and-down profile that rewards efficient climbers and fearless descenders, and a summit near 6,000 feet that avoids altitude headaches without losing the punch. With 1.5x points on offer, we make the case for why European stars could cross the Atlantic and why sub-two hours might be in play.We unpack the “why here” question through logistics and strategy. Seattle's international access makes travel simple, while the terrain delivers classic skyrunning character without sprawling altitude or complex permitting. Then we zoom out: how ISF certification interacts with the World Series, the signals from Whiteface and Broken Arrow, and whether a U.S. skyrunning series is waiting in the wings. We compare philosophies too, contrasting Golden Trail's media-friendly flower loops with skyrunning's traditional aesthetic lines and discussing why a tighter global calendar could sharpen competition and improve storytelling.This is also a conversation about athlete pathways. If more U.S. events gain certification, short-trail standouts, collegiate converts, and VK specialists can build toward European icons like Matterhorn and Trofeo Kima without crossing oceans for every test. We talk rumors, real implications for the Northeast and Pacific Northwest scenes, and how brands and athletes might respond if skyrunning gains momentum here. Hit play to catch our hot takes, practical race analysis, and the questions that will define the next phase of American mountain running. If you enjoy the show, follow, share with a trail friend, and leave a quick review—what race should be the next U.S. skyrunning stop?Follow James on IG - @jameslauriello Follow the Steep Stuff Podcast on IG - @steepstuff_pod Use code steepstuffpod for 25% off your cart at UltimateDirection.com!

Send us a textWelcome to The Oncology Journal Club Podcast Series 3Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology NetworkWelcome back to The Oncology Journal Club podcast, your essential dose of the latest oncology research, expert analysis and our trademark blend of healthy scepticism and bad jokes.Hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson.This week's episode really does contain multitudes, with an incredibly eclectic mix of papers.Craig looks at the effectiveness of cancer control measures and optimising drug dosages.Kate talks us through interactions between solid neoplasms and the microbiome and shares a curious paper on extra virgin olive oil.CJ tackles a sobering paper on substandard anticancer medications and what lessons can be learnt from KEYNOTE-585 and Matterhorn in gastric cancer.We've a great selection of Quick Bites and a heartfelt discussion about taboo thoughts and the challenges carers of people with brain cancer face.To learn more about The Oncology Network, subscribe to our free weekly Newsletter and listen to other fantastic podcasts, visit our website: www.oncologynetwork.com.au. You'll also find the Show Notes on the website with links to papers, a transcript and bios of our hosts.

The happiest place on earth has some seriously fascinating holiday history! In this episode, Jake covers some standout moments from past Christmas celebrations at Disneyland. Learn about the origins of the Candlelight Processional and the jaw-dropping Christmas decoration that once adorned the Matterhorn!Listen along and join the Dis-cussion on social media @neverlandnavco

James and Katie went to the OG theme park - the Happiest Place on Earth, Disneyland!Well, they did it like three months ago at this point but now we finally have time to talk about it!Don't forget to like, subscribe, rate, review, comment, share, and ride the damn Matterhorn.SUBSCRIBE TO OUR PATREON:https://www.patreon.com/cticketpodCHECK US OUT ON YOUTUBE:https://youtube.com/@cticketpod?si=ig6ODv0zvbaXuFPhFOLLOW US ON SOCIAL MEDIA:TIKTOK: https://www.tiktok.com/@cticketpodINSTAGRAM: https://www.instagram.com/cticketpod/TWITTER: https://twitter.com/CTicketPodEMAIL US:cticketpod@gmail.comMERCH AVAILABLE NOW!https://www.teepublic.com/user/the-c-ticket-podcastThe C-Ticket Podcast: It's not the best theme park podcast, but it's probably somebody's favorite!Hosted by Nick D'Ambrosia and James PerlasMusic:Delightful D Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0 Licensehttp://creativecommons.org/licenses/by/3.0/

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma. Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including: • The significance of the study in the context of recent FDA approvals and treatment advancements. • Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab. • The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes. • Management of side effects and clinical pearls for practitioners. We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions. Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, share, and subscribe for more practice-changing updates in oncology! #MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology

Len Testa and Jim Hill continue No Negative November with a look at Zootopia's new 4D adventure, listener trip-planning wisdom, and the surprising book that inspired Disneyland's first mountain. NEWS Zootopia: Better Zoo-gether debuts at Animal Kingdom — The Tree of Life theater gets a major refresh with a new story, water gags, and a charming Benjamin Clawhauser animatronic. Holiday highlights return — Tree of Life Awakenings now plays nightly thanks to early sunsets, and the beloved Merry Menagerie puppet experience returns November 14. Storytime with Santa Deadpool — A holiday twist hits Avengers Campus, complete with meta Christmas jokes and Greek Orthodox canon accuracy. Listener questions answered — From the best Bay Lake Tower villas for New Year's Eve fireworks to whether it's time for Tables in Wonderland to return. Disney's shrinking parades — Why the Festival of Fantasy looks lighter on dancers and floats—and how Disney's still managing two parades a day at Magic Kingdom. FEATURE The Making of the Matterhorn — Jim shares the wild story of how a 1950s family film led Walt Disney to send a postcard from Switzerland that simply said: “Build this.” How Banner in the Sky and Third Man on the Mountain inspired Walt's alpine obsession. Why the Matterhorn nearly became a luge-style attraction (yes, really). The creative legacy of director Ken Annakin, whose films also led to Swiss Family Treehouse and Sleeping Beauty Castle. Full show notes available here: Show Notes HostsJim Hill — X/Twitter: @JimHillMedia | Instagram: @JimHillMedia | Website: jimhillmedia.comLen Testa — BlueSky: @lentesta.bsky.social | Instagram: @len.testa | Website: touringplans.com Support the Show Love what we do? Support The Disney Dish on Patreon for exclusive bonus shows and early access: patreon.com/jimhillmedia Follow Us Facebook: @JimHillMediaNews | YouTube: @jimhillmedia | TikTok: @jimhillmedia Produced by Edited by Dave Grey Produced by Eric Hersey — Strong Minded Agency Sponsor This episode is brought to you by Unlocked Magic, powered by DVC Rental Store. Save up to 10% on Disney park and event tickets, including Mickey's Very Merry Christmas Party and Jollywood Nights — only at unlockedmagic.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Len Testa and Jim Hill continue No Negative November with a look at Zootopia's new 4D adventure, listener trip-planning wisdom, and the surprising book that inspired Disneyland's first mountain. NEWS Zootopia: Better Zoo-gether debuts at Animal Kingdom — The Tree of Life theater gets a major refresh with a new story, water gags, and a charming Benjamin Clawhauser animatronic. Holiday highlights return — Tree of Life Awakenings now plays nightly thanks to early sunsets, and the beloved Merry Menagerie puppet experience returns November 14. Storytime with Santa Deadpool — A holiday twist hits Avengers Campus, complete with meta Christmas jokes and Greek Orthodox canon accuracy. Listener questions answered — From the best Bay Lake Tower villas for New Year's Eve fireworks to whether it's time for Tables in Wonderland to return. Disney's shrinking parades — Why the Festival of Fantasy looks lighter on dancers and floats—and how Disney's still managing two parades a day at Magic Kingdom. FEATURE The Making of the Matterhorn — Jim shares the wild story of how a 1950s family film led Walt Disney to send a postcard from Switzerland that simply said: “Build this.” How Banner in the Sky and Third Man on the Mountain inspired Walt's alpine obsession. Why the Matterhorn nearly became a luge-style attraction (yes, really). The creative legacy of director Ken Annakin, whose films also led to Swiss Family Treehouse and Sleeping Beauty Castle. Full show notes available here: Show Notes HostsJim Hill — X/Twitter: @JimHillMedia | Instagram: @JimHillMedia | Website: jimhillmedia.comLen Testa — BlueSky: @lentesta.bsky.social | Instagram: @len.testa | Website: touringplans.com Support the Show Love what we do? Support The Disney Dish on Patreon for exclusive bonus shows and early access: patreon.com/jimhillmedia Follow Us Facebook: @JimHillMediaNews | YouTube: @jimhillmedia | TikTok: @jimhillmedia Produced by Edited by Dave Grey Produced by Eric Hersey — Strong Minded Agency Sponsor This episode is brought to you by Unlocked Magic, powered by DVC Rental Store. Save up to 10% on Disney park and event tickets, including Mickey's Very Merry Christmas Party and Jollywood Nights — only at unlockedmagic.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Mousedebaters talk Sounds of DisneylandThis week on Mousedebaters, we're putting our mouse ears to the test—literally. Join Luke, Brittany, and Kami as we try to identify real sounds from videos of our Disneyland trip. Is that the Matterhorn's yeti roar or just Luke's stomach before churros? Hard to say.Then we wrap up spooky season with a perfectly deranged game of “Disney Halloween Musical Casting.” From Young Frankenstein to Little Shop of Horrors, we recast your favorite creepy musicals with Disney and Muppet characters. Think Fozzie as Igor, Ursula as Audrey II, maybe Goofy as... Frankenstein's monster?! I don't know, you'll just have to listen to find out.As always, we're not your kids' Disney podcast. PG-13 chaos for grown-up ears only.

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice. Episode Highlighted: •⁠  ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer. •⁠  ⁠STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities. •⁠  ⁠MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies. •⁠  ⁠FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma. Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms. #ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine

Send us a textA ruby-red cocktail, a carousel in view, and a debate we've wanted to settle for ages: which Fantasyland truly delivers the magic? We put Disneyland and Magic Kingdom head-to-head on the four things that matter most to park fans—food, layout, rides, and shows—and the results aren't as simple as coast pride.We start with the Handsome Brute and a quick reality check on price, then dive into dining. Florida brings the firepower with Cinderella's Royal Table, Be Our Guest, Gaston's Tavern, and a spread of quick-service spots, while Anaheim counters with the fan-favorite Red Rose Tavern and that coveted Grey Stuff. From value to character dining, we map where each land feeds your day best.Then we shift to what you feel the second you step through the castle. Disneyland's Fantasyland is a storybook square—tight, kinetic, and overflowing with classics like Mr. Toad, Alice, Pinocchio, and the canal boats, anchored by the Matterhorn. Magic Kingdom stretches wider, with Seven Dwarfs Mine Train at its core and Storybook Circus on the edge; it's generous in space and rich in queues, but less cohesive in spirit. On shows and characters, Florida wins with Mickey's PhilharMagic, Enchanted Tales with Belle, Princess Fairytale Hall, and reliable meet-and-greets. On rides, California's stacked lineup and intimate flow make a powerful case for the original.We wrap with practical strategy: rope drop plans, when to chase Peter Pan, how better queues can redeem longer waits, and why layout shapes the mood of your entire day. If you love the deep comfort of Disney nostalgia or crave a day packed with dining and character moments, you'll know exactly where to go next.If this helped you choose your next park day, follow the show, share it with a Disney-loving friend, and leave a quick review to tell us which Fantasyland gets your vote.

Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT Southwestern Medical Center; and Udhayvir S. Grewal, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Each doctor focused on a specific disease type, highlighting the most important abstracts in colorectal cancer, pancreatic neuroendocrine tumors (NETs), and upper gastrointestinal cancers. The Phase 3 MATTERHORN Trial (NCT04592913) Results from MATTERHORN demonstrated that adding durvalumab (Imfinzi) to 5-fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel (FLOT) improved overall survival (OS) compared with FLOT plus placebo in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, regardless of pathological status.1 In the intention-to-treat population, the median OS was not reached in either arm, and the hazard ratio (HR) was 0.78 (95% CI, 0.63-0.96; P = .021). Notably, the improvement was observed regardless of PD-L1 status; in patients with PD-L1–positive disease, the HR was 0.79 (95% CI, 0.63-0.99), and in patients with PD-L1–negative disease, the HR was 0.79 (95% CI, 0.41-1.50). “This, I believe, will seal durvalumab plus FLOT as the standard of care for resectable [gastric/GEJ] cancers,” said Brown. The Observational ASPEN Study (NCT03084770) The ASPEN study showed that active surveillance was a safe approach for patients with low-grade, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NETs) fewer than 2 centimeters in size.2 Of the 1000 patients enrolled in the trial, 20 patients died, of whom 18 underwent active surveillance and 2 underwent surgery. Nineteen of the deaths were unrelated to pancreatic NETs; 1 death in the surgery arm was related to a pancreatic NET. After surgery, 5 patients had disease relapse or progression. With a median follow-up of 42 months (IQR, 25-60), the OS analysis showed a P value of 0.530.  “This really settles the debate on whether or not to surgically operate on patients with a [pancreatic NET] size of [fewer] than 2 centimeters and shows that active surveillance is a safe option for these patients with pancreatic NETs [fewer] than 2 centimeters in size and non-functional NETs,” said Grewal.  Data From the Phase 2/3 FOxTROT (NCT00647530) and Phase 2 NICHE-2 (NCT03026140) Trials Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) achieved a clinically meaningful and statistically significant improvement in long-term outcomes, including responses and survival, compared with chemotherapy strategies in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced colon cancer.3 In NICHE-2, neoadjuvant nivolumab plus ipilimumab achieved a 3-year disease-free survival (DFS) rate of 100% compared with 80% (95% CI, 73%-85%) with all chemotherapy strategies in FOxTROT (P

Please Follow us on: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠ ⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook ⁠⁠⁠⁠⁠! In this episode, Kimberly and Tommaso apologize for the delay in their latest release. They then dive into a discussion about their favorite meals in Italy, looking back at 28 years of travel. Key Points: Kimberly and Tommaso offer a sincere apology for the delayed episode. They recap their previous discussion on favorite cities and regions. The main topic is their favorite meals in Italy, spanning 28 years of travel experiences. Episode Highlight: First Italian Meals in Cervinia Kimberly and Tommaso recount a ski trip from Zermatt, Switzerland, down to Cervinia, Italy. Kimberly describes their incredible hunger after the challenging ski descent. Tommaso recalls his memorable Zuppa Valdostana, a rich beef broth soup with bread and fontina cheese. Kimberly shares her delight in eating polenta with fontina cheese and red wine. They reminisce about a Raclette lunch with Matterhorn views, marking it as a beautiful outdoor dining experience. Meals in Lago di Como and Florence: Kimberly shares a story about visiting friends in Lago di Como, coinciding with their annual Brunello bottling celebration. Tommaso describes enjoying five to seven-year-old Brunello with grilled beef prepared by an international meat dealer. Kimberly celebrates her 40th birthday lunch at Alvalu in Tremezzo, featuring simple tomato pasta, cured meats, and a beautiful fruit tart. They both recall the unique grappa infused with blueberries, made by monks. Rome and Florence Culinary Experiences: Tommaso shares his first carbonara experience in Rome in 2021, describing it as a moment of pure paradise. Tommaso notes the relaxed dining pace in Italy, contrasting it with the faster pace in America. Kimberly describes a simple, attractive enoteca in Rome where they enjoyed another carbonara and a mozzarella di bufala appetizer. Tommaso discusses his anticipation and enjoyment of Bisteca Fiorentina in Florence, splitting it with a friend. Kimberly remembers the bright and loud atmosphere of the Florentine restaurant, a contrast to their preferred dining setting. Southern Italy and Pizza Delights: Kimberly highlights her favorite meals in Puglia, particularly a salad with tuna, mozzarella, and local vegetables, drizzled with Puglian olive oil and served with local bread. Tommaso praises the simplicity and quality of Puglian bread. Tommaso declares his favorite pizza was in Ischia, preferring a heartier style with onions, mushrooms, and prosciutto. Kimberly recounts a standout Napolitano pizza experience in Torino, found in a residential neighborhood across the river. Tommaso reflects on the ongoing challenge of finding the “next best something” in Italian cuisine. Coffee and Truffles in Torino: Kimberly raves about the bicherine, a coffee layered with dark chocolate, espresso, and frothy cream, at Cafe Bicherine in Torino. Tommaso praises a wide noodle pasta with shaved white truffles, enjoyed during truffle season in Torino, paired with a bottle of Barolo. Join Kimberly and Tommaso as they revisit their most cherished Italian meals, sharing anecdotes and insights from decades of culinary adventures. Kimberly and Tommaso share their most memorable meals from 28 years of Italian travels, from ski trips to Roman trattorias. This episode explores Italy's diverse culinary landscape and the joy of savoring food and culture.

We talk lost Disney lore, a new giveaway, getting wet on the Matterhorn and more!  

The Matterhorn Fit All-Path Series is here including the Western, Ontario, and Quebec. Coach Eric will be leading the charge with the All-Path Ontario event with NCAA Division 1 and OHL programs set to join!Visit matterhornfitevents.com to REQUEST REGISTRATION!Wondering where we've been? Big announcement coming soon!

Send us a textJim Clash covers extreme adventure and classic rock. Over three decades of writing for Forbes, Clash, who holds an MBA from Columbia University, has penned four books, most recently Amazon bestseller “Amplified,” about ‘60s music. His first-person stories include supersonic flights in eight separate aircraft pulling up to 9 Gs and flying to 84,000 ft; driving a Bugatti at 253 mph and Indy cars at 200 mph; expeditions to the North and South Poles; summiting the Matterhorn and 23,000-ft. Aconcagua; a C-130 flight through Category V Hurricane Dorian; chasing tornadoes; riding jet skis on 60-ft waves in Portugal; a U-2 flight to the edge of space; bullfighting; being shot point-blank in a ballistics jacket, and more. Interviews include Neil Armstrong, Mario Andretti, John Glenn, Edmund Hillary, Roger Bannister, Grace Slick, Joe Frazier, Chuck Yeager and Edward Teller. For fun, Jim gives 170-mph rides at Daytona speedway. He's a former director at The Explorers Club.See more of Jim's work at Forbes and on his FaceBook pageGet Jim's books here on AmazonSupport this Podcast:  buy me a coffeeHosted by Michael J. ReinhartMichaelJReinhart.com   Whiskey and a Map:  Stories of Adventure and Exploration.  #space #JamesClash #biggestwaves #supersonicflight

Im Juli 1895 steht Albert Mummery, einer der besten Bergsteiger seiner Zeit, vor der höchsten Wand der Welt. 4.500 Meter ragt die Rupal-Wand vor ihm in die Höhe. Es ist der erste ernsthafte Versuch, einen Achttausender zu besteigen. Die Expedition endet tödlich, wie viele weitere Besteigungsversuche am Nanga Parbat im Himalaya. Wir sprechen in der Folge darüber, wie der Nanga Parbat zum Schicksalsberg der Deutschen wurde und wie es Hermann Buhl 1953 erstmals auf den Gipfel schaffte. //Erwähnte Folgen - GAG360: Unglück am Matterhorn – https://gadg.fm/360 - GAG453: Pemmikan und der Pelzhandel in Nordamerika – https://gadg.fm/453 - GAG269: Monika Ertl und ein Mord im Generalkonsulat – https://gadg.fm/269 //Literatur - Ralf-Peter Märtin: Nanga Parbat. Wahrheit und Wahn des Alpinismus, 2002. - Kriemild Buhl: Mein Vater Hermann Buhl: Der Ausnahmebergsteiger, 2024. - Podcast „Messner – ein extremes Leben“: https://www.ardaudiothek.de/sendung/messner-ein-extremes-leben/urn:ard:show:32b583b0e97d83b1/ //Aus unserer Werbung Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/GeschichtenausderGeschichte // Wir sind jetzt auch bei CampfireFM! Wer direkt in Folgen kommentieren will, Zusatzmaterial und Blicke hinter die Kulissen sehen will: einfach die App installieren und unserer Community beitreten: https://www.joincampfire.fm/podcasts/22 //Wir haben auch ein Buch geschrieben: Wer es erwerben will, es ist überall im Handel, aber auch direkt über den Verlag zu erwerben: https://www.piper.de/buecher/geschichten-aus-der-geschichte-isbn-978-3-492-06363-0 Wer Becher, T-Shirts oder Hoodies erwerben will: Die gibt's unter https://geschichte.shop Wer unsere Folgen lieber ohne Werbung anhören will, kann das über eine kleine Unterstützung auf Steady oder ein Abo des GeschichteFM-Plus Kanals auf Apple Podcasts tun. Wir freuen uns, wenn ihr den Podcast bei Apple Podcasts oder wo auch immer dies möglich ist rezensiert oder bewertet. Wir freuen uns auch immer, wenn ihr euren Freundinnen und Freunden, Kolleginnen und Kollegen oder sogar Nachbarinnen und Nachbarn von uns erzählt! Du möchtest Werbung in diesem Podcast schalten? Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio: https://www.seven.one/portfolio/sevenone-audio

Jen and Frank chat with Troy and Mimi from Disney Assembled Podcast about their recent trip to Disneyland. On this episode…

Gaza-Rückkehrer stehen vor dem Nichts, Schweizer Bäcker: Ärger über günstiges Aldi-Brot, Tunesien: Hölle für Migrantinnen und Migranten, YouTuber klettert alleine aufs Matterhorn

In today's episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress. Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT05403554) investigating NI-1801 in patients with heavily pretreated, mesothelin-expressing platinum-resistant epithelial ovarian cancer. Premal H. Thaker, MD, MS, the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology and director of Gynecologic Oncology Clinical Research at Siteman Cancer Center in Saint Louis, Missouri, discussed the anticipation for findings from a multi-omic analysis of the phase 3 AtTEnd/ENGOT-EN7 trial (NCT03603184) of atezolizumab in patients with endometrial cancer and data demonstrating that the WES-derived Aneuploidy Score may identify patients with mismatch repair–deficient endometrial cancer who derive reduced benefit from immunotherapy. Zev Wainberg, MD, the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research at UCLA, shared his anticipation for new data in gastrointestinal oncology, particularly the overall survival results from the phase 3 MATTERHORN trial (NCT04592913) of durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel in patients with resectable gastric and gastroesophageal cancer, which are expected to provide pivotal updates following previously reported event-free survival outcomes. Sagus Sampath, MD, an associate clinical professor and medical director of the Department of Radiation Oncology at City of Hope in Duarte, California, highlighted the phase 2 NorthStar trial (NCT03410043) evaluating osimertinib (Tagrisso) with or without local consolidative therapy in patients with metastatic EGFR-mutated non–small cell lung cancer (NSCLC).

Send us a textGet ready to ROCK with Sam, Kevin, and Amanda as we honor the legacy of Fred Joerger—the rockwork artist and model builder who helped shape the very foundation of Disneyland. From miniature models of Sleeping Beauty Castle to the towering peaks of the Matterhorn and Big Thunder Mountain, Fred's work turned blueprints and concept art into believable masterpieces. We explore his career before, during, and after his time as an Imagineer, and how his fingerprints continue to tell stories at the parks today. Then, in our Imagineering Armchair segment, we dream up new ways to bring naturalistic detail and miniature magic back into the parks—just as Fred would have done. We invite you to become Armchair Imagineers with us! Please share your thoughts and join the conversation about this episode and more on our Discord!Don't miss her stories, laughs, and the Disney magic that keeps us all coming back for more!Join us in our completely free Discord https://discord.gg/4nAvKTgcRnCheck out all of our amazing sponsors!Getaway Todayhttps://www.getawaytoday.com/?referrerid=8636If you want to book a Disney Vacation, please use our friends at Getaway Today. Also, if you call 855-GET-AWAY and mention Walt's Apartment, you will get a special dose of magic Where In The Park The Podcast-“Discover the history behind the details of Disney parks and more on the Where In The Park podcast”https://whereinthepark.comCheck Out Sunken City Designs - from the mind of Louis Medinahttps://sunkencitydesigns.bigcartel.comWe are proud to be part of the Disney Podcast Family , checkout all the other great shows below https://linktr.ee/DisneyPodcastFamily

The Matterhorn, Nestlé Chocolate, and a long-standing history of neutrality, Switzerland has it all. However, the Swiss were too busy enjoying all those comforts and fell asleep at the wheel for the past few decades...Join the Patreon here: https://www.patreon.com/PeterZeihanFull Newsletter: https://mailchi.mp/zeihan/the-swiss-are-screwed

Anne Lindboe er Oslos ordfører, men visste du at hun er en verdensvant klatrer, som har besteget både Matterhorn og Mont Blanc? Einar får henne i studio for å lære mer om dette, hvordan det er å dra rundt i verden og bestige gigantiske steinrøyser, hvilke topper hun har i kikkerten og en debreif av en eksotisk tur til den undervurderte ferieperlen Slovenia.Er du keen på å høre om de respektive landene som fjellene befinner seg i? Skaff deg et Podimoabonnement og hør landepisodene på podimo.no/198land, da vel!Produsert av Martin Oftedal, PLAN-B Hosted on Acast. See acast.com/privacy for more information.

This episode of the The Coffee Club, Daily Show Podcast, starts with a discussion about upcoming sporting events, from the Winter Olympics in Milan and Cortina, Italy, to the Summer Olympics in Los Angeles. Janae and Ronnie also touch on some terrifying and sad topics, including a hoax about Carson Wentz's father's death and a discussion about scams that prey on people's emotions. They then shift gears to a more uplifting topic: the upcoming Veterans Honor Flight. Later, the hosts share some "Did You Know" facts, discuss what they love about fall, and debate whether listening to audiobooks counts as reading. The conversation also covers some "terrifying" but normal aspects of daily life, like driving, aging, and childbirth, and the hosts share some wild news stories about a bear attack in Yellowstone and a youth baseball practice struck by stray bullets. The highlight of the episode is an interview with Patrick Kirby of Do Good Better Consulting on Nonprofit Day. Patrick shares insights on the current state of nonprofit giving, emphasizing the shift towards large donors and the importance of showing donors the impact of their contributions. The show wraps up with more news, including the latest from NASA and an update on the Matterhorn ride at Disneyland. Standout Moments: Winter Olympics are Next Year: The hosts realize the Winter Olympics are happening in Milan and Cortina, Italy, in February 2026. (00:00:27) A Hoax About Carson Wentz's Father: A discussion about a social media hoax claiming the death of Carson Wentz's father. (00:02:40) Veterans Honor Flight: Details are shared about the upcoming Veterans Honor Flight on Tuesday, the 30th, asking the community to welcome the 204 veterans home at the Fargodome. (00:05:32) North Dakota Reading Proficiency: A concerning statistic is revealed: the average reading proficiency rate for students in North Dakota is only 44%. (00:08:18) The Terrors of Everyday Life: The hosts talk about everyday activities that are "terrifying," including driving, having children, and ride-sharing. (00:20:46) The State of Nonprofits: Guest Patrick Kirby explains how nonprofit donations have changed since COVID, with fewer individual donors but larger contributions from major donors. (00:23:45) The Importance of Gratitude: Patrick Kirby stresses the importance of nonprofits showing gratitude and demonstrating the impact of donations. (00:26:00) Reindeer are Real: The hosts share a surprising "Did You Know" moment about reindeer being real animals. (00:35:54) Disneyland's Submarine Voyage: The history of the original Disneyland submarine…

You might think Marie is a travel planner. You might think she is a health care professional. Stick around, because once you hear it, you might just change your mind about . . . EPIC MARIE. Yep. Epic Marie is here to dish about her experiences at Universal and also tell us how wrong we are about all of our previous episodes. In this episode, you will be able to: Discover what makes Epic Universe a game-changer in Orlando's theme park scene and why it might just become your new favorite spot. Compare Universal's Epic Universe and Disneyland to uncover which park offers the best experiences for your next epic adventure. Identify the must-try rides at Epic Universe that deliver unforgettable thrills and unique storytelling you won't find anywhere else. Explore the secrets of the Wizarding World of Harry Potter Ministry of Magic and why it's a must-see for any Potter fan visiting Epic Universe. Uncover the top dining options at Epic Universe that combine great flavors with immersive atmospheres to fuel your park day perfectly. The key moments in this episode are:00:00:01 - Introduction and Single Riders Dating App Humor 00:06:00 - Spokes and Hub Crawl Podcast Structure Explained 00:16:17 - Planning and Staying Near Epic Universe Theme Park 00:18:58 - Optimal Time and Attractions to Experience at Epic Universe 00:26:40 - Layout and Ride Variety in Super Nintendo World vs. Other Lands 00:29:43 - Dark Universe Experience and Scary Atmosphere Insights  00:36:11 - Ministry of Magic Ride Review and Technical Breakdown 00:41:30 - Exploring Epic Universe's Kids' Attractions and Ride Experiences 00:43:40 - Disney and Universal Coasters 00:52:10 - Future Expansion and Theming Predictions for Epic Universe 00:55:20 - Universal's Epic Universe vs. Disney World00:58:45 - Supreme Resort Concierge Insights and Podcast Ad Break 01:00:50 - Sleeping Beauty vs. Cinderella Castle 01:03:45 - Everest, Matterhorn, Indiana Jones, and Dinosaur 01:09:42 - Opinions on Haunted Mansion Holiday and Listener Perspectives  01:13:18 - Fun Trivia and Correcting Disney Facts  ------ Hey, have you called J. R. Trimpe yet? Do you need music? Because you should really call him. https://trimpe.org Also, Marie @land_world_sea_with_marie Learn more about your ad choices. Visit megaphone.fm/adchoices

Mary Poppins would say, "Just a Spoonful of Sugar Helps the Medicine go Down". Well, I've seen that happen as it's been my.privilege to work with organizations big and small, public, private and non-profit. Many of them come to me because they want their organization to be something more like Disney. They want a place where people enjoy working and even have fun at it. In truth, few organizations work harder than Disney. And at the end of the day, it's work. But despite the hard times, the difficult circumstances, and the day-to-day challenges, leaders stay positive despite the circumstances. There are Disney inspired lessons that can show us all how to keep a sense of humor, how to create a space for fun, how not to take themselves too seriously, and even how to find joy in accomplishing the impossible. From the boardroom to the Matterhorn; from Canoe Races to Goofy's Mystery Tour--join us as we learn lessons from Disney leaders past and present about how to create fun--even at work! ________________________________________________________________ Disney Insights YouTube Page--Check it out and subscribe. DisneyInsights.com--So many resources at our home site. Be sure to subscribe to receive notice of upcoming podcasts. Disney Insights Facebook Page--Come join and interact in conversation with others. My newest book, A Century of Powerful Disney Insights, Volume I 1923-1973, The Walt & Roy Disney Years is available!  Also, check out my two of my other books, The Wonderful World of Customer Service at Disney and Disney, Leadership and You.  Also, for those examining other business benchmarks beyond Disney, check out Lead with Your Customer: Transform Culture and Brand Into World-Class Excellence. ________________________________________________________ Check out Zanolla Travel to book your next vacation! David & Leah Zanolla ZanollaTravel.com Owner/Agents (309) 863-5469 ____________________________________________________________________ Performance Journeys This podcast and post is provided by J. Jeff Kober and Performance Journeys, which celebrates more than 20 years as a training and development group bringing best in business ideas through books, keynotes, workshops, seminars and online tools to help you take your organization to the next level. Want a Keynote Speaker? More than just nice stories, I offer proven insight and solutions having worked in the trench. Need Consulting? I've worked for decades across the public, private and non-profit arena.  Need Support? We offer so many classroom, online, and other resources to help you improve your customer service delivery, leadership excellence, and employee engagement. Contact us today, and let us help you on your Performance Journey!

Dreaming of panoramic views and sparkling alpine lakes on your Swiss Alps travel adventure? If alpine hiking, charming mountain villages, and unforgettable mountain excursions are on your wishlist, this episode is for you.In this episode, I'm joined by Claudia Wyss from Zermatt Cableways as we explore one of Switzerland's most scenic walks, the famous Five Lakes Hike. Starting from Blauherd and making our way to the stunning Stellisee, Claudia shares her best tips for hiking in Switzerland, from choosing the right gear to finding the best photo spots for that perfect Matterhorn reflection.You'll hear about other must-do adventures in Zermatt, including riding the Gornergrat railway, taking in the views from Matterhorn Glacier Paradise, and heading up to Rothorn for sweeping mountain panoramas. We also chat about family-friendly adventure activities like mountain carts, kickbikes, and playgrounds by alpine lakes.Claudia's insider knowledge is your must-have Switzerland travel guide, with suggestions for timing your hikes, enjoying local cuisine, and making the most of seasonal offers like sunrise tours.Whether you're looking for your first taste of alpine hiking or you've explored Switzerland before and want to discover more hidden gems, this episode will leave you inspired, informed, and ready to lace up your hiking boots.Tune in now to discover the five reasons the Five Lakes Hike should be on your Switzerland travel itinerary.Safe travels,Carolyn

Kim and her daughter Mia just got back from a mother-daughter trip to Switzerland. They celebrated her high school graduation with a grad trip and since Mia loves mountains and she was already going to be in France with a school trip, Switzerland was her top choice! They visited Geneva, Zermatt and the Jungfrau Region because they really wanted to focus on the mountains. Altogether they spent eight nights in Switzerland and they moved around a lot. The itinerary included: 1 night in Geneva 2 nights in Zermatt to see the Matterhorn 2 nights in Grindelwald 2 nights in Wengen 2 nights in Lucerne If you are going to Switzerland and you really want to spend time in the mountains, skip Geneva and Lucerne and focus more on the smaller towns, not the cities. Their favorite town was Zermatt for hiking and also wine tasting. Grindelwald was the other favorite because of the hotel and the view of Eiger. Some of the activities included: Visit the old town in the cities (e.g. Geneva) Hiking (which are harder than you might expect even on trails described as easy, use Google Maps to see elevation, buy or bring hiking poles if you can and are checking a bag) Cable cars (which are pricey) Matterhorn Glacier (you can also ski even in the summer) Alpine slides / mountain coaster / ziplines The train is a great way to get around the country and if you use a Swiss Rail Pass you also get transportation on some of the cable cars (but not all). It makes it very easy because you don't need to worry about buying tickets. First class will give you more seating options and it is less crowded so it is quieter. It is hard to use the trains if you have large luggage as some of the trains are more for locals/commuters. Try to pack light if you can or use a luggage forwarding service. It is better to stay longer in each destination as you spend a lot of time transiting up and down the mountains via train/cable car. Basing yourself in Murren or other smaller towns ends up with a lot of time waiting for transportation. It makes more sense to stay in Grindelwald, Interlaken, or Lauterbrunnen. When planning a trip, be sure to plan at least six to nine months in advance if you want to stay in town and at the better hotels. Also, when considering different hotels, the hospitality is wonderful but look closely at the amenities that are offered. Most don't have air conditioning but it wasn't needed in the mountains. Some hotels have screens on the windows but not all and there are a lot of flies and some mosquitoes. Keep in mind that shops close early (6-7 pm) and that busses also stop running by 7:00 pm in small towns. Hotels and meals are very expensive in Switzerland, especially now that the dollar is weak against the CHF and Euro. Main entrees are 30-50 CHF per person, salads 12-19 CHF, and beer was cheap but wine was expensive. To save money, you can buy wine or beer at the grocery store to enjoy before you go out. Drink sizes are also very small. The food is a lot of fondue, cheese, pasta, raclette, and chocolate. Other regions might have more regional specialties. Otherwise there are a lot of burgers and international cuisine. If you do have allergies, there are a lot of peanuts and other nuts being served as a snack or included in dishes. Credit cards can be used almost everywhere. In all the tourist areas, everyone spoke English. They were less accommodating in the city or non-tourist establishment. Be sure to pack and wear sunscreen. It is hard to find places to refill a water bottle so you may want to carry your own snacks and drinks.

✨ Ever wondered what's really behind that mysterious door in New Orleans Square? Or what goes on inside the Matterhorn when you're not on the bobsleds?In this exclusive Patreon episode, I'm taking you on a tour of the hidden side of Disneyland—the places most guests never get to see. From Club 33 and the now-legendary Dream Suite to backstage breakrooms, secret tunnels, and yes… even a basketball court tucked inside a mountain.We'll peek behind closed doors, above Main Street windows, and into the cast-only corners that keep the magic running. Whether you're a casual fan or a diehard Disneyland detective, you're going to love these stories, secrets, and little-known facts.Thank you for supporting Mix In Some Magic on Patreon—this episode is just for you.

Scott McKibben is the CEO and Co-founder of Matterhorn Venture Partners, a Chicago-based firm that specializes in acquiring, developing, and managing value-added industrial real estate across the US. With a career spanning over 30 years, Scott has overseen more than $10.6 billion in transactions and has developed and acquired more than 80 million square feet of industrial and office properties — making a significant impact on the commercial real estate industry. A former NCAA Division I tennis player at DePaul University and a graduate of the University of Wisconsin, Scott brings a competitive and disciplined approach to deal-making and team building. In this episode… Many real estate professionals face the challenge of scaling profitably while adapting to unpredictable market cycles. With rising interest rates, fierce competition, and shifting project economics, building a resilient investment firm requires more than capital — it demands vision, adaptability, and the ability to attract top-tier talent. How can today's dealmakers structure firms that weather downturns and still deliver strong returns? Scott McKibben, a seasoned commercial real estate executive, shares how he launched his firm with a lean, MVP-style approach — assembling a team of trusted colleagues and offering shared ownership to create true alignment. With over $10 billion in transactions and 80 million square feet of industrial and office projects under his belt, Scott reflects on lessons from both legacy deals and new ventures. He explains why backing local partners as 50-50 co-owners leads to entrepreneurial agility, how persistence and adaptability helped him navigate projects like the Citadel Center pivot, and why securing equity before chasing deals is a discipline he swears by. In this episode of the Inspired Insider Podcast, Dr. Jeremy Weisz interviews Scott McKibben, Co-founder and CEO of Matterhorn Venture Partners, about building high-impact real estate ventures. Scott shares his journey from leadership at Brennan Investment Group to launching MVP, strategies for recruiting top talent, and the importance of transparency and trust with investors. He also dives into the mindset that fuels long-term success, the role of relationships in sourcing deals, and how sports taught him the grit and discipline needed to thrive in real estate.

The lads return with a tiki-fueled tales of: summer brain fog, terrifying theme park rides, and a very unexpected encounter at Vegas' Golden Tiki. They dive into the new Walt Disney animatronic at Disneyland—does it honor the man or haunt your dreams? (he has a pillow for that). Plus: a punk rock museum detour, brutal tiki bar opinions (sorry, Palm Springs), and how Jungle Cruise jokes still come in handy at Costco. If you love Disney parks, tiki culture, or just laughing at weird Vegas stories, this is the episode is for you.

Jeffrey Adolf Epstein. Isn't there a guy who owns the Smithsonian called Smith something? 1000 butts a day. I Didn't Order THCeeeeeeEEEEeeeeeeeeee! Inherently Voluptuous Rabbits. Riki Tiki Toddler. Do elephants have paws? Cause I'd like really wanted to know. Wasn't the head of the Manson Family called Charlie Something? Smoke Pizza Everyday. What's the Matterhorn? It's a bird, It's a plane! It's a squiggly line! Spy Women. Papa Ibbott Dunks on Everyone. Both Sides of the Aisle Are Covered in Cheetos Dust. None of your business with Wendi and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

Jeffrey Adolf Epstein. Isn't there a guy who owns the Smithsonian called Smith something? 1000 butts a day. I Didn't Order THCeeeeeeEEEEeeeeeeeeee! Inherently Voluptuous Rabbits. Riki Tiki Toddler. Do elephants have paws? Cause I'd like really wanted to know. Wasn't the head of the Manson Family called Charlie Something? Smoke Pizza Everyday. What's the Matterhorn? It's a bird, It's a plane! It's a squiggly line! Spy Women. Papa Ibbott Dunks on Everyone. Both Sides of the Aisle Are Covered in Cheetos Dust. None of your business with Wendi and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

Alex brings the history for The Matterhorn, a Disneyland California classic. Mags and Ryan try to stay on course, but things sometimes go off the tubular steel track. .For more Dizneyverse, head over to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dizneyverse.com⁠⁠ or check us out on Instagram @Dizneyverse ⁠https://www.instagram.com/dizneyverse/one⁠Check out our Tee-Public page for a shirt or sticker. ⁠http://tee.pub/lic/tEDcAPdSVFA⁠